Bottom line
XLV vs MEDX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and MEDX (Horizon Kinetics Medical ETF) share a meaningful slice of their top holdings — about 47% by weight.
XLV is cheaper at 0.08% vs 0.85% — a difference of $77 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +5.8% for MEDX.
Updated Nov 19, 2026
XLV vs MEDX side by side
| XLV | MEDX | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Roundhill |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.85% |
| Annual cost per $10k | $8 | $85 |
| 10-yr cost on $10k (prospectus) | $103 | $1,049 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +28.4% |
| 5-yr return (annualized) | +8.1% | +5.8% |
| 10-yr return (annualized) | +9.8% | +5.7% |
| Best quarter | +14.5% | +15.0% |
| Worst quarter | −12.7% | −12.9% |
| Net assets (fund) | $40.6B | $19.1M |
| Number of holdings | 65 | 33 |
| Portfolio turnover | 2% | % |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | MEDX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +28.4% | −13.9% |
| 2024 | +2.5% | −4.7% | +7.2% |
| 2023 | +2.0% | −6.0% | +8.0% |
| 2022 | −2.1% | +4.2% | −6.3% |
| 2021 | +25.9% | +10.6% | +15.3% |
| 2020 | +13.3% | +9.0% | +4.2% |
| 2019 | +20.7% | +16.0% | +4.6% |
| 2018 | +6.3% | +1.7% | +4.6% |
| 2017 | +21.7% | +10.7% | +11.0% |
| 2016 | −2.8% | −8.0% | +5.2% |
Source: Fund prospectus bar charts
Holdings overlap
8 of XLV's top 25 holdings also appear in MEDX's top 25.
| Holding | XLV | MEDX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 18.46% |
| Johnson & Johnson | 10.64% | 5.59% |
| AbbVie Inc | 7.74% | 8.85% |
| Merck & Co Inc | 5.52% | 3.96% |
| Amgen Inc | 3.40% | 3.91% |
| Pfizer Inc | 2.39% | 2.86% |
| Bristol-Myers Squibb Co | 2.05% | 4.42% |
| Regeneron Pharmaceuticals Inc | 1.08% | 2.06% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
MEDX top 10
- Eli Lilly & Co — 18.46%
- US Bank Mmda - Usbgfs 7 — 9.19%
- AbbVie Inc — 8.85%
- Novartis AG — 6.89%
- Johnson & Johnson — 5.59%
- Alkermes PLC — 5.53%
- AstraZeneca PLC — 4.98%
- Ionis Pharmaceuticals Inc — 4.53%
- Bristol-Myers Squibb Co — 4.42%
- Merck & Co Inc — 3.96%
FAQ
What is the difference between XLV and MEDX?
Which is cheaper, XLV or MEDX?
Should I own both XLV and MEDX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.